A randomized clinical study of Lu AA21004 in the prevention of relapse in patients with major depressive disorder
- 9 April 2012
- journal article
- research article
- Published by SAGE Publications in Journal of Psychopharmacology
- Vol. 26 (11) , 1408-1416
Abstract
The efficacy and tolerability of Lu AA21004 in the prevention of relapse of major depressive disorder (MDD) in patients in remission after acute treatment was evaluated. Patients (n=639) aged 18–75 years with a primary diagnosis of MDD with a current major depressive episode (MDE) ≥4 weeks’ duration, at least one prior MDE and a MADRS total score ≥26 received 12-week, open-label Lu AA21004 at 5 or 10mg/day. Patients in remission (MADRS ≤10) at both weeks 10 and 12 were assigned to double-blind treatment with either placebo or Lu AA21004 (fixed dose from Week 8).Patients (n=396) were treated, after random assignment to placebo (n=192) or Lu AA21004 (n=204). The primary analysis of time to relapse (full-analysis set, Cox proportional hazard model) showed a statistically significant difference in favour of Lu AA21004 versus placebo with a hazard ratio of 2.01 (95% confidence interval: 1.26–3.21; p=0.0035). The proportion of patients who relapsed was 13% in the Lu AA21004 group (n=27) and 26% in the placebo group (n=50). The withdrawal rates due to adverse events were 8% (open-label), and 3% (placebo) and 8% (Lu AA21004) (double-blind). Thus, Lu AA21004 was effective in preventing relapse of MDD and was well tolerated as maintenance treatment.Keywords
This publication has 19 references indexed in Scilit:
- A double-blind, randomized, placebo-controlled, active reference study of Lu AA21004 in patients with major depressive disorderInternational Journal of Neuropsychopharmacology, 2011
- Discovery of 1-[2-(2,4-Dimethylphenylsulfanyl)phenyl]piperazine (Lu AA21004): A Novel Multimodal Compound for the Treatment of Major Depressive DisorderJournal of Medicinal Chemistry, 2011
- Prediction of Recurrence in Recurrent DepressionThe Journal of Clinical Psychiatry, 2010
- Do Efficacy and Effectiveness Samples Differ in Antidepressant Treatment Outcome?The Journal of Clinical Psychiatry, 2010
- Relevance of Exclusion Criteria in Antidepressant Clinical TrialsJournal of Clinical Psychopharmacology, 2007
- Prevention of relapse in generalized anxiety disorder by escitalopram treatmentInternational Journal of Neuropsychopharmacology, 2005
- The Mini International Neuropsychiatric Interview (MINI). A short diagnostic structured interview: reliability and validity according to the CIDIEuropean Psychiatry, 1997
- A New Depression Scale Designed to be Sensitive to ChangeThe British Journal of Psychiatry, 1979
- A RATING SCALE FOR DEPRESSIONJournal of Neurology, Neurosurgery & Psychiatry, 1960
- THE ASSESSMENT OF ANXIETY STATES BY RATINGPsychology and Psychotherapy: Theory, Research and Practice, 1959